These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 10668347)
1. [Sense and nonsense of post-authorization surveillance]. de Mey C Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347 [No Abstract] [Full Text] [Related]
2. Industry reneges on postmarketing trial commitments. Bouchie A Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074 [No Abstract] [Full Text] [Related]
3. FDA increases focus on postmarketing studies. Goozner M J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650 [No Abstract] [Full Text] [Related]
4. Lessons from Eprex for biogeneric firms. Louët S Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539 [No Abstract] [Full Text] [Related]
5. [Sense and nonsense in post-authorization surveillance]. de Mey C Med Klin (Munich); 2000 May; 95(1 Spec No):77-82. PubMed ID: 10851853 [TBL] [Abstract][Full Text] [Related]
6. Schroeder Lecture. Worst pills, best pills. Wolfe SM Health Matrix Clevel; 2006; 16(2):785-96. PubMed ID: 16948255 [No Abstract] [Full Text] [Related]
7. Informed consent to postmarketing research. British rules outlaw disguised promotion of drugs. Wells F BMJ; 1995 Sep; 311(7006):692. PubMed ID: 7549671 [No Abstract] [Full Text] [Related]
8. Secrecy and product liability litigation. Brahams D Lancet; 1990 Sep; 336(8717):737-8. PubMed ID: 1975905 [No Abstract] [Full Text] [Related]
9. Global harmonization is not all that global: divergent approaches in drug safety. Castle GH; Kelly B Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662 [No Abstract] [Full Text] [Related]
10. ["There are clear criteria for product surveillance studies"]. Throm S MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777 [No Abstract] [Full Text] [Related]
12. Equivocal role of micelles in Eprex adverse events. Schellekens H; Crommelin DJ Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346 [No Abstract] [Full Text] [Related]
13. Equivocal role of micelles in Eprex adverse events. Smiell JM Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347 [No Abstract] [Full Text] [Related]
14. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
15. FDA seeks advice on track-and-trace systems. Traynor K Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794 [No Abstract] [Full Text] [Related]
16. Highly lauded drug assessment program under attack. Silversides A CMAJ; 2008 Jul; 179(1):26-7. PubMed ID: 18509096 [No Abstract] [Full Text] [Related]
17. Drug regulation 2056. Bezold C; Peck J Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091 [No Abstract] [Full Text] [Related]
18. [Guidelines for prescription drugs; special interests are counterproductive]. Kirsten WD Internist (Berl); 1999 Aug; 40(8):224-5. PubMed ID: 10532841 [No Abstract] [Full Text] [Related]
19. Lessons learned from the COX-2 advisory hearings. Somberg J Am J Ther; 2005; 12(2):105. PubMed ID: 15767826 [No Abstract] [Full Text] [Related]
20. Quality, safety and efficacy of follow-on biologics in Japan. Yamaguchi T; Arato T Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]